HM Payson & Co. lifted its holdings in Sanofi (NASDAQ:SNY) by 12.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,201 shares of the company’s stock after purchasing an additional 1,358 shares during the period. HM Payson & Co.’s holdings in Sanofi were worth $593,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of SNY. Reby Advisors LLC bought a new position in shares of Sanofi in the 4th quarter worth approximately $35,000. Arkadios Wealth Advisors bought a new position in shares of Sanofi in the 4th quarter worth approximately $36,000. Charter Oak Capital Management LLC bought a new position in shares of Sanofi in the 4th quarter worth approximately $40,000. JJJ Advisors Inc. increased its holdings in Sanofi by 193.8% in the 4th quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock worth $41,000 after acquiring an additional 562 shares in the last quarter. Finally, Accel Wealth Management purchased a new stake in Sanofi in the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 6.93% of the company’s stock.
Several equities research analysts recently issued reports on the stock. Barclays reissued an “equal weight” rating on shares of Sanofi in a report on Tuesday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sanofi in a report on Friday, January 15th. They issued a “sell” rating for the company. UBS Group reissued a “buy” rating on shares of Sanofi in a report on Tuesday, January 19th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, February 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $53.00.
Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 4th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.88 by ($0.15). Sanofi had a net margin of 14.49% and a return on equity of 24.77%. The company had revenue of $9.38 billion for the quarter, compared to analysts’ expectations of $9.39 billion. During the same period last year, the business earned $1.34 earnings per share. The company’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Sanofi will post 3.49 earnings per share for the current year.
The firm also recently announced an annual dividend, which will be paid on Wednesday, May 26th. Investors of record on Tuesday, May 4th will be issued a $1.9061 dividend. The ex-dividend date of this dividend is Monday, May 3rd. This is a positive change from Sanofi’s previous annual dividend of $1.21. This represents a dividend yield of 3.2%. Sanofi’s dividend payout ratio (DPR) is 35.24%.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.
Read More: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.